GB1492930A - Virus growth - Google Patents
Virus growthInfo
- Publication number
- GB1492930A GB1492930A GB5062273A GB5062273A GB1492930A GB 1492930 A GB1492930 A GB 1492930A GB 5062273 A GB5062273 A GB 5062273A GB 5062273 A GB5062273 A GB 5062273A GB 1492930 A GB1492930 A GB 1492930A
- Authority
- GB
- United Kingdom
- Prior art keywords
- virus
- cells
- feline
- cell strain
- nutrient medium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A61K39/265—Infectious rhinotracheitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
1492930 Feline virus vaccines AFG (STALHAM) Ltd 31 Oct 1974 [31 Oct 1973] 50622/73 Heading A5B [Also in Division C6] Antigenic material effective against a virus disease in cats e.g. feline panleucopenia, feline rhinotracheitis and feline picornaviruses is prepared by obtaining feline lung tissue free from virus disease, preparing a cell strain of the feline lung tissue, forming a culture of the cell strain, a tissue free virus corresponding to the virus disease and a nutrient medium, and growing the culture, and either (a) inactivating the virus or (b) attenuating the virus by serial passage in the cell strain. A vaccine comprises the antigenic material in an administrable form. A feline lung tissue may be prepared under aseptic conditions, disaggregating the lung tissue either by mechanical means or with an enzyme and culturing or sub - culturing the disaggregated lung tissue by serial passages in a nutrient medium preferably until a cell strain is obtained being either a diploid or heteroploid cell strain which is free from extraneous virus. The disaggregation may be performed in a buffered salt solution containing trypsin to form a suspension of cells which is transferred to the nutrient medium where it is cultured at 35‹C to 40‹C. The culture may be formed either (a) by seeding the virus to a suspension of the cell strain in the nutrient medium or (b) by adding the virus to the cell strain in the form of a confluent monolayer with subsequent addition of the nutrient medium such as by allowing the virus to adsorb on to the cells which are maintained at 20‹C to 40‹C preferably for 30 to 120 minutes is allowed for adsorption after which a quantity of the nutrient medium at a rate of 10 to 50 ml of the medium for every million viable cells and the whole is incubated at 30‹ to 40‹C desirably until a cytopathic effect takes place on the cells and wherein the culture is harvested when the cytopathic effect is near to completion e.g. when it has attained from 80% to 100%. After harvesting the cells and the liquid medium are separated by centrifuging and the liquid medium containing the extracellular virus is collected, the cells being then broken down for liberation of the cell associated virus. The cells may be treated by repeated freezing and thawing followed by separation of antigenic material from the cell debris by centrifugation. The nutrient medium may be Eagles Basal Medium maintained at a pH of 7.0 to 7.4 by the use of a buffering agent and containing calf serum or calf foetal serum.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB5062273A GB1492930A (en) | 1974-10-31 | 1974-10-31 | Virus growth |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB5062273A GB1492930A (en) | 1974-10-31 | 1974-10-31 | Virus growth |
Publications (1)
Publication Number | Publication Date |
---|---|
GB1492930A true GB1492930A (en) | 1977-11-23 |
Family
ID=10456663
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB5062273A Expired GB1492930A (en) | 1974-10-31 | 1974-10-31 | Virus growth |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB1492930A (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0011864A1 (en) * | 1978-11-30 | 1980-06-11 | The Wellcome Foundation Limited | Attenuated strain of feline infectious peritonitis virus, method for preparing it and vaccine comprising it |
EP0011865A1 (en) * | 1978-11-30 | 1980-06-11 | The Wellcome Foundation Limited | Feline infectious peritonitis vaccine and process for its preparation |
EP0027347A1 (en) * | 1979-10-16 | 1981-04-22 | Norden Laboratories, Inc. | Feline infectious peritonitis virus, its preparation and vaccines containing it |
US4287178A (en) * | 1974-03-25 | 1981-09-01 | Pitman-Moore, Inc. | Feline rhinotracheitis vaccine and production and use thereof |
US5374424A (en) * | 1986-10-03 | 1994-12-20 | Miles Inc. | Multivalent felv-infected feline vaccine |
-
1974
- 1974-10-31 GB GB5062273A patent/GB1492930A/en not_active Expired
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4287178A (en) * | 1974-03-25 | 1981-09-01 | Pitman-Moore, Inc. | Feline rhinotracheitis vaccine and production and use thereof |
EP0011864A1 (en) * | 1978-11-30 | 1980-06-11 | The Wellcome Foundation Limited | Attenuated strain of feline infectious peritonitis virus, method for preparing it and vaccine comprising it |
EP0011865A1 (en) * | 1978-11-30 | 1980-06-11 | The Wellcome Foundation Limited | Feline infectious peritonitis vaccine and process for its preparation |
EP0027347A1 (en) * | 1979-10-16 | 1981-04-22 | Norden Laboratories, Inc. | Feline infectious peritonitis virus, its preparation and vaccines containing it |
US4303644A (en) * | 1979-10-16 | 1981-12-01 | Norden Laboratories, Inc. | Feline infectious peritonitis virus vaccines |
US5374424A (en) * | 1986-10-03 | 1994-12-20 | Miles Inc. | Multivalent felv-infected feline vaccine |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Malmquist et al. | Production of equine infectious anemia antigen in a persistently infected cell line | |
Boroff | Study of toxins of Clostridium botulinum III: Relation of autolysis to toxin production | |
US3865689A (en) | Method of producing carcinoembryonic antigens | |
EP0027347B1 (en) | Feline infectious peritonitis virus, its preparation and vaccines containing it | |
US4070453A (en) | Diploid porcine embryonic cell strains, cultures produced therefrom, and use of said cultures for production of vaccines | |
EP0011864B1 (en) | Attenuated strain of feline infectious peritonitis virus, method for preparing it and vaccine comprising it | |
GB1492930A (en) | Virus growth | |
US4169761A (en) | Process for the cultivation of viruses | |
US3585266A (en) | Live rabies virus vaccine and method for the production thereof | |
Kono et al. | An epidemic of Getah virus infection among racehorses: properties of the virus | |
CN105535958A (en) | Newcastle disease virus, infectious bronchitis and fowl adenovirus triple inactivated vaccine | |
WO2004110484A1 (en) | Method for producing a live tissue-cultural vaccine against influenza virus | |
NO310305B1 (en) | Matrix with adherently bound cells, as well as the method of producing late-summer meningoencephalitis (FSME) virus antigen | |
CA2178553A1 (en) | Marek's disease vaccine | |
Fieldsteel et al. | Propagation of infectious canine hepatitis virus in cultures of pig and ferret kidney | |
Petkus et al. | Pure spherules of Coccidioides immitis in continuous culture | |
US3432595A (en) | Melanoma cell line of canine origin,its propagation and use,and vaccines derived therefrom | |
US3228840A (en) | Virus culture | |
GB1471262A (en) | Virus growth | |
EP0013188A2 (en) | Parainfluenza virus vaccine and its preparation | |
US3418210A (en) | Hamster ascites tumor cell line bhk 21/c.13/t.6/ascites useful in submerged serum-free agar cultures to support virus growth | |
Faulkner et al. | Propagation of a strain of rabbit fibroma virus in tissue-culture | |
Matumoto et al. | Behavior of bovine ephemeral fever virus in laboratory animals and cell cultures | |
NL2031523B1 (en) | Cell culture method of chlamydia abortus and use thereof | |
KR840001215A (en) | Manufacturing method of improved strain strain |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PS | Patent sealed | ||
PCNP | Patent ceased through non-payment of renewal fee |